Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.

Journal Article

We sought to induce primate immunodeficiency virus-specific cellular and neutralizing antibody (nAb) responses in rhesus macaques (RM) through a bimodal vaccine approach. RM were immunized intragastrically (i.g.) with the live-attenuated Listeria monocytogenes (Lm) vector Lmdd-BdopSIVgag encoding SIVmac239 gag. SIV Gag-specific cellular responses were boosted by intranasal and intratracheal administration of replication-competent adenovirus (Ad5hr-SIVgag) encoding the same gag. To broaden antiviral immunity, the RM were immunized with multimeric HIV clade C (HIV-C) gp160 and HIV Tat. SIV Gag-specific cellular immune responses and HIV-1 nAb developed in some RM. The animals were challenged intrarectally with five low doses of R5 SHIV-1157ipEL-p, encoding a heterologous HIV-C Env (22.1% divergent to the Env immunogen). All five controls became viremic. One out of ten vaccinees was completely protected and another had low peak viremia. Sera from the completely and partially protected RM neutralized the challenge virus > 90%; these RM also had strong SIV Gag-specific proliferation of CD8⁺ T cells. Peak and area under the curve of plasma viremia (during acute phase) among vaccinees was lower than for controls, but did not attain significance. The completely protected RM showed persistently low numbers of the α4β7-expressing CD4⁺ T cells; the latter have been implicated as preferential virus targets in vivo. Thus, vaccine-induced immune responses and relatively lower numbers of potential target cells were associated with protection.

Full Text

Duke Authors

Cited Authors

  • Lakhashe, SK; Velu, V; Sciaranghella, G; Siddappa, NB; Dipasquale, JM; Hemashettar, G; Yoon, JK; Rasmussen, RA; Yang, F; Lee, SJ; Montefiori, DC; Novembre, FJ; Villinger, F; Amara, RR; Kahn, M; Hu, S-L; Li, S; Li, Z; Frankel, FR; Robert-Guroff, M; Johnson, WE; Lieberman, J; Ruprecht, RM

Published Date

  • August 5, 2011

Published In

Volume / Issue

  • 29 / 34

Start / End Page

  • 5611 - 5622

PubMed ID

  • 21693155

Electronic International Standard Serial Number (EISSN)

  • 1873-2518

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2011.06.017

Language

  • eng

Conference Location

  • Netherlands